For Investors

Independent technology reviews are incredibly valuable for family offices, VC groups, angels, and other investors assessing current portfolio performance or planning for the future. Identifying cutting-edge technologies or pinpointing issues in ongoing development programs can save significant time and resources.

As an independent partner, our objective technology assessments cover drug, device, and other life science technologies, making us a valuable asset to any investment group. Many of our team are qualified investors themselves, understanding the early-stage life science ecosystem from scientific, medical, business, and investor perspectives.

We specialize in expert technical reviews of emerging technologies and assessment of intellectual property estates. While we do not provide specific investment advice, we are committed to offering the best objective technical assessments based on our subject matter expertise.
We have a growing team of medical and scientific professionals capable of assessing technologies and their relevance within specific disease areas. Furthermore, through our extensive network, we can quickly connect with experts in areas not currently covered by our immediate team.